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Decreased Progesterone Binding and Attenuated Progesterone Action in Cultured
Human Breast Carcinoma Cells Treated with Epidermal Growth Factor1
Jay C. Sarup,2 Kanury V. S. Rao, and C. Fred Fox3
Department of Microbiology and Molecular Biology Institute, University of California, Los Angeles, California 90024-1489
ABSTRACT
Specific progesterone binding by cultured human breast carcinoma
T47D, MCF-7, and ZR75-1 cells was decreased 25-40% by epidermal
growth factor (EGF), with a 50% effective dose of 0.1 UMEGF. Studies
with the soluble and paniculate fractions prepared after homogenization
of T47D cells grown in glass roller bottles revealed equivalent EGF-
induced decreases in progesterone binding to receptors in both fractions.
Equilibrium progesterone binding studies with these soluble and partic-
ulate fractions revealed that EGF decreased the receptor number, but
had no effect on affinity. With cells grown adherent to plastic dishes,
EGF treatment induced a greater decrease in binding to receptors re
covered i;i the particulate fraction, than to receptors recovered in the
soluble fraction. The decrease in progesterone binding induced by 20 MM
EGF was maximal after 2 min of cellular EGF treatment for receptors
recovered in the soluble fraction, but was only half-maximal after 15 min
for receptors recovered in the particulate fraction. Decreased progester
one binding persisted for at least 8 days in cells cultured with 1 mi EGF.
Either insulin or EGF stimulated T47D cell proliferation by two- to
threefold with a 50% effective dose of 100 n\i for insulin and 0.1 UM for
EGF. The progestin, R5020, decreased T47D cell growth by 30% with a
50% effective dose of 1 IIM. Either EGF or insulin antagonized the
inhibitory effect of R5020 on cell reproduction, but progestins did not
antagonize the growth stimulatory response of cells to EGF. Progestins
increased the number of EGF receptors within 12 h of their addition to
T47D cells, but this response was lost after 6 days. These data show that
EGF or progesterone can regulate the receptor number of the other, but
for cell reproduction, the effect of EGF is dominant over that of proges
tins.
INTRODUCTION
Epidermal growth factor is a mitogen which stimulates many
mesenchymal and epithelial cell lines to grow in culture (see
reviews in References 1-4). EGF4 induces a pleiotypic response,
characterized by stimulations in transport of low molecular
weight compounds, glycolytic activity, nucleic acid and protein
synthesis, and phosphorylation of membrane-associated and
intracellular proteins (reviewed in References 1 and 5).
Like a number of other transforming gene products, the EGF
receptor is a protein tyrosine kinase (6), which phosphorylates
itself as well as other substrates and the kinase activity is
stimulated by EGF (reviewed in References 1, 4, 5, and 7). A
role for protein phosphorylation by the EGF receptor in growth
factor-induced cell division is supported by the demonstration
that site-specific mutagenesis at the ATP binding site destroyed
both receptor kinase and mitogenic activities (8). Purified avian
oviduct progesterone receptor is a high affinity substrate for
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phosphorylation by purified EGF and insulin receptors (9, 10),
but not for platelet-derived growth factor receptor. This obser
vation stimulated our interest in testing for regulatory linkages
between EGF or insulin actions and progesterone binding and
action in cultured breast carcinoma cells.
Linkage between steroid and peptide hormone actions has an
established history. Dexamethasone increases cellular EGF
binding to human foreskin fibroblast cells (11) and insulin
binding to 3T3-C2 Swiss mouse fibroblasts (12). Moreover,
glucocorticoids potentiate mitogenic effects of EGF (11) and
insulin-induced stimulation of 2-deoxyglucose transport on
short term exposure (12 h), but decrease 2-deoxyglucose uptake
in the presence of insulin upon longer exposure (24-48 h) (12).
Progestins increase insulin (13) and EGF binding (14) to cul
tured human T47D breast carcinoma cells. On the other hand,
androgens decrease EGF binding in rat prostate glands in vivo
(15). Insulin down-regulates estrogen binding and antagonizes
growth inhibition by antiestrogens in cultured human MCF-7
breast carcinoma cells (16).
High EGF receptor number has been associated with low
estrogen receptor (17, 18) or progesterone receptor (18) con
tents in human breast cancer biopsies. Estrogen induces EGF-
and IGF-like peptides which have been detected by competitive
EGF binding and by radioimmunoassay, respectively, in me
dium conditioned by growth of MCF-7 cells (19). TGF-a-like
activity has been detected in medium conditioned by growth of
cultured MCF-7 breast carcinoma as indicated by stimulation
of anchorage-independent growth of normal rat kidney cells in
soft agar and inhibition of EGF binding to membranes derived
from human epidermoid carcinoma A431 cells (20). IGF-I
mRNAs have been detected in MCF-7 cells by Northern blot
analysis, and IGF-I-like activity has been detected in medium
conditioned by growth of MCF-7 cells by radioimmunoassay
(21). TGF-/3-like material has been detected in medium condi
tioned by growth of cultured human MCF-7 breast carcinoma
cells in the presence of antiestrogen (22).
EGF stimulates the growth of both human neoplastic (23,
24) and normal human (25) and mouse (26, 27) mammary
epithelial cells in culture. EGF induces lobuloalveolar devel
opment in estrogen and progesterone primed immature mouse
mammary glands in whole organ culture (28). Studies with
sialoadenectomized mice indicate that EGF is important for
mammary gland development (29, 30) and milk production by
the gland (29). While progestins inhibit growth of cultured
MCF-7 (31) and T47D (13) human breast carcinoma cells,
progesterone is essential for alveolar growth of mammary gland
and it inhibits lactogenesis (reviewed in Reference 32). In
normal mouse mammary epithelial cells, EGF inhibits casein
synthesis (27) by differentially inhibiting the expression of
casein genes (33).
Since purified progesterone receptors are substrates for pu
rified EGF and insulin receptors (9, 10) and since EGF and
progesterone have opposing effects on growth of both normal
and neoplastic mammary epithelial cells, we have tested cul
tured human breast carcinoma cells for regulation of progester
one receptor number by EGF. In this report, we provide evi-
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dence that EGF affects progesterone receptor action on cultured
human breast carcinoma cells by down-regulating progesterone
binding and attenuating progestin-induced inhibition of cell
growth.
MATERIALS AND METHODS
Materials. [l,2,6,7-3H]Progesterone (91 Ci/mmol) and ACS (aque
ous counting scintillation fluid) were obtained from Amersham Cor
poration (Arlington Heights, IL). [3H]R5020 ([ \1 a-methyl-^H]-17,21 -
dimethyl- 19-norpregn-4,9-diene-3,20-dione) and unlabeled R5020 were
from Du Pont NEN Products (Boston, MA). Unlabeled progesterone,
leupeptin, dithiothreitol. EDTA, EGTA, and phenylmethylsulfonyl
fluoride, bovine serum albumin (Cohn fraction V), and bovine pan
creatic insulin were purchased from Sigma Chemical Company (St.
Louis, MO). Unless otherwise stated, other chemicals were of reagent
grade.
Mouse EGF was isolated from male mouse submaxillary glands (Pel-
Freeze Biologicals, Rogers, AR) as described by Savage and Cohen
(34). Its purity was determined by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (35) and its biological activity was assessed
by measuring stimulation of [3H]thymidine incorporation in serum-
starved 3T3 cells where it exhibited an ED50 of 0.1 nM (36). [I25I]EGF
was prepared using chloramine T and the specific activity was 1-2 x
IO18cpm/mol (37).
Cells and Cell Culture. Human breast carcinoma T47D, MCF-7, and
ZR75-1 cells, obtained from Marc Lippman (National Cancer Institute,
Bethesda, MD), contained estrogen, progesterone, glucocorticoid, and
androgen receptors (38, 39). T47D cells contain very high levels of
progesterone receptors [2.5 x IO6 sites/cell (40); or 1221 fmol/mg
cytosol protein (38)], but very low levels of glucocorticoid (19 fmol/mg
cytosol protein), estrogen (3 fmol/mg cytosol protein), and androgen
(31 fmol/mg cytosol protein) receptors (38). Estradiol does not induce
progesterone receptors in T47D cells (40; confirmed by us) or in the
MCF-7 cells used in the present study. We did not test ZR75-1 cells
for induction of progesterone receptors by estradici.
Cells were maintained routinely in 75-cm2 polystyrene culture flasks
in RPMI 1640 medium (Irvine Scientific, Santa Ana, CA) containing
5% untreated fetal bovine serum (GIBCO, Chagrin Falls, OH) and 10
Mg/ml gentamicin at 37Â°Cin a humidified atmosphere of 5% CO2 and
95% air. Cell monolayers were grown to 90% confluency, treated with
trypsin (0.25% trypsin in Hanks' balanced salt solution) at 37Â°C,
suspended in 10 ml of RPMI 1640 medium containing 5% untreated
fetal bovine serum, and passed (2:10, 1:10, 0.3:10 splits for ZR75-1,
T47D, and MCF-7, respectively) once weekly with a change in culture
medium on the third day. Cells used in all studies described here were
between passages 6 and 25.
For the adherent cell hormone binding studies described in Fig. 1,
cells were grown in 24-well polystyrene dishes (Corning Glass Works,
Corning, NY) for 3 days to a final density of 10s cells/cm2 (50%
confluent). Cells were cultured only in the first and the fourth row wells
of the four-row 24-well dish, since cells in the inner and outer wells
sometimes grew at different rates. For the experiment described in Fig.
3, T47D cells were cultured in 840-cm2 surface area borosilicate glass
roller bottles (Wheaton, Mellville, NJ) in Dulbecco's modified Eagle's
medium (Irvine Scientific, Irvine, CA) and Ham's F-12 (GIBCO) in a
1:1 ratio, containing untreated 10% calf serum (M.A. Bioproducts,
Walkersville, MD) and 10 Â¿ig/mlgentamicin. Roller bottles were gassed
with CO2, and the cells were cultured at 37Â°Cwith a change in medium
on the third day of culture and used when approximately 80% confluent.
Cells for the experiments described in Figs. 1-3 were grown in RPMI
1640 medium containing untreated 5% fetal bovine serum. We observed
that dextran-coated charcoal treatment of fetal bovine serum by a
published procedure (38) resulted in a failure of 80% of the cells to
attach to the culture dish upon plating. Subsequently, we found that
reduction of the temperature for dextran-coated charcoal treatment to
22Â°Cproduced serum supporting attachment of all cells plated. Cells
for experiments described in Figs. 4-8 were grown in 55-cm2 plastic
Petri plates for 2-3 days in RPMI 1640 containing 5% DCC-FBS and
achieved approximately 80 to 90% confluency. The cells were then
plated in 1.0 ml/well (2-cm2 24-well dish) or in 4.0 ml/well (10-cm2 6-
well dish) of RPMI 1640 medium containing DCC-FBS. There was a
lag of 2 days before growth of T47D cells resumed following transfer
from medium containing untreated serum to medium containing 5%
DCC-FBS.
Serum-free Cell Culture. Cells plated in 55-cm2 Petri plates in RPMI
1640 medium containing 5% DCC-FBS and grown for 2 days were
transferred into 10-cm2 6-well culture dishes at 50,000 cells/well in
RPMI 1640 medium containing 5% DCC-FBS. The culture medium
was replaced 18 h later with 4.0 ml of serum-free medium (RPMI 1640
containing dextran-coated charcoal treated 0.1% Cohn fraction V bo
vine serum albumin). After 24 h, the medium was replaced with fresh
serum-free medium and at this point, hormones were added where
indicated. Cells were grown with changes in serum-free culture medium,
together with fresh additions of hormones, every 2 days.
Preparation of Dextran-coated Charcoal-treated Serum or Bovine
Serum Albumin. Endogenous steroids were removed from sera by a
modification of the procedure of Horwitz et al. (38), except that the
temperature during charcoal treatment was 22Â°C.One part (100 ml) of
dextran-coated charcoal suspension [0.025% (w/v) dextran and 0.5%
(w/v) Norit A charcoal in 10 mM Tris-HCl (pH 7.5)] was sedimented
at 30,000 x g.min. The pellet was suspended in 100 ml of fetal bovine
serum or bovine serum albumin (10 mg/ml) and the suspensions were
incubated at 22Â°Cfor 60 min with gentle shaking on a rotating platform.
The suspensions were centrifuged at 30,000 x g. min to remove charcoal
and the treated preparations were sterilized by ultrafiltration through
0.2-nm pore Nylon filters (Nalgene, Rochester, NY). When 20 nM
[3H]progesterone was added to sera as a tracer, >99% of the label was
removed following the charcoal treatment. We observed that over 80%
of the cells plated in fetal bovine serum treated with dextran-coated
charcoal at 45Â°Cas described by Horwitz et al. (38) did not attach to
the culture dish even 2 days after plating. When the temperature of
charcoal treatment of sera was changed to 22Â°C,this phenomenon was
not observed. Addition of human plasma-derived fibronectin (Collabo
rative Research, Lexington, MA) at 50 ng/ml to culture medium
containing the 45Â°Cdextran-coated charcoal-treated fetal bovine serum
resulted in attachment of approximately 80% of the cells plated in 24
h.
Preparation of Cytosol and Paniculate Fractions. T47D cells grown
in glass roller bottles were washed twice with 50 ml/roller bottle of
Tris-buffered saline (150 mM NaCl and 10 mM Tris-HCI, pH 7.4).
Cells (1.5 x 10* cells/roller bottle) were resuspended by incubating at
37Â°Cfor 15 min in 15 ml/roller bottle with Tris/saline/EDTA [25 mM
Tris-HCl, 1 mM EDTA, 150 mM NaCl, and l mM Na2HPO4 (pH 7.4
at 37Â°C)],rolling continuously at 4 rpm. The suspended cells obtained
from two roller bottles were collected by a 4,000 x g. min centrifugaron,
washed twice with 40 ml of homogenization buffer [10 mM Tris-HCl,
1 mM Na2EDTA, 5 mM EGTA, 2 mM phenylmethylsulfonyl fluoride,
2 mM dithiothreitol, 40 //n/ml leupeptin, 10 mM sodium molybdate,
and 10% (v/v) glycerol (pH 7.4)], and homogenized with 50 strokes of
a Dounce homogenizer in 4.0 ml of ice-cold homogenization buffer.
The homogenate was centrifuged at 40,000 x g.min and the superna
tant fraction was collected. The particulate fraction was suspended in
4.0 ml of homogenization buffer and centrifuged again at 40,000 x g/
min. The supernatant fractions were combined and adjusted to 9.0 ml
final volume with homogenization buffer to yield the cytosolic fraction.
The cytosolic fraction was diluted 5-fold and 50 //I of this dilution was
used for progesterone binding assay.
In experiments conducted with adherent T47D cells grown in 55-
cm2 Petri plates (to approximately 50% confluency), the cells were
washed twice with 10 ml/dish of homogenization buffer and removed
with 3.0 ml/plate of this buffer at 0Â°Cusing a rubber policeman. Cells
(5 x IO6)obtained from each Petri plate were disrupted at 0Â°Cin 200
n\ of homogenization buffer with 25 strokes of Potter-Elvhjem homog
enizer. The soluble and particulate fractions were separated by a 40,000
x g/min centrifugation at 4Â°C.The particulate fraction was suspended
in 50 /(I of homogenization buffer and centrifuged as above; the super
natant fractions were then combined.
Solubilization of Particulate Fraction-associated Progesterone Recep-
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tors with High Ionic Strength Buffer. Washed paniculate fraction de
rived from 3x10* cells obtained from two roller bottles was suspended
in 5.0 ml of homogenization buffer containing 0.5 M KC1. The partic-
ulate fraction derived from 5 x IO6 cells grown on a Petri plate was
suspended in 75 //I of homogenization buffer containing 0.5 M KC1.
The fractions were incubated with gentle shaking on a rotating platform
at 4Â°Cfor 60 min and centrifuged at 40,000 x g/min. The supernatant
fraction containing solubilized receptors was used for progesterone
binding experiments. Tests for progesterone binding to the particulate
fraction showed that receptor extraction was generally >90% complete.
Dextran-coated Charcoal Assay for Progesterone Receptors. Aliquots
(50 MÃ–of the cytosol or high ionic strength extract of the particulate
fraction were combined with 50 ^1 of homogenization buffer containing[3H]progesterone at the concentrations indicated. The samples were
incubated either at 4Â°Cfor 16 h or at 23Â°Cfor 1 h. They were then
chilled at 0Â°Cfor 5 min and combined with one part (v/v) of dextran-
coated charcoal suspension [0.025% (w/v) dextran and 0.5% (w/v)
Norit A charcoal in homogenization buffer] (41). After mixing by vortex
action, the samples were incubated at 0Â°Cfor 5 min, with 2 min
intermittent mixing, and centrifuged at 47,000 x g/min. A 50-^1 aliquot
of the supernatant fraction was assayed for radioactivity in 7 ml of
ACS.
Progesterone Binding to Adherent Cells. Progesterone binding to
adherent cells was conducted with cell monolayers grown in 2-cm2 24-
well culture dishes. The cells were washed twice with 2 ml of proges
terone binding medium (10 HIM 4-(2-hydroxyethyl)-l-piperazineeth-
anesulfonic acid-buffered RPMI 1640, pH 7.2) per well per wash. The
cells were incubated at room temperature (22-23Â°C)in 0.5 ml of binding
medium containing 20 IIM [3H]progesterone. Replicate samples were
incubated with 2 /<\i unlabeled progesterone for determination of non
specific binding. The cells were washed three times at 0Â°Cin progester
one binding medium to remove unbound progesterone and solubilized
in 300 fi\ of l M NaOH at 60Â°Cfor 60 min. Aliquots (150 /il) were
neutralized with HC1 and assayed by scintillation counting for bound[3H]progesterone in 7 ml of ACS.
EGF Binding to Adherent Cells. Substratum adherent cells grown in
2-cm2 24-well culture dishes were washed twice with EGF binding
medium (RPMI 1640 medium, 10 mM 4-(2-hydroxyethyl)-l-pipera-
zineethanesulfonic acid, and 0.1% bovine serum albumin, pH 7.2) and
incubated at 22Â°Cin 300 Â¿tlof this medium containing 20 nM [125I]EGF
for 60 min. Replicate samples were incubated in the presence of 2 ^M
unlabeled EGF to determine nonspecific binding. The cells were washed
rapidly at ()"( ' (within 30 s) three times with 2 ml of binding medium
per well. Bound [I25I]EGF was determined by gamma counting follow
ing solubilization of the cells at 22Â°Cfor 30 min in 300 pi of l M
NaOH.
Cell Counting. Cells were rinsed once with Tris/saline/EDTA solu
tion [25 mM Tris-HCI, 1 mM EDTA, 150 mM NaCl, and 1 mM
Na2HPO4 (pH 7.4)] containing 10 Â¿ig/mlphenol red and treated at
37Â°Cfor 45 min with 0.13% trypsin in Tris/saline/EDTA. Cells grown
in roller bottles were suspended in Tris/saline/EDTA as described
under "Preparation of cytosol and particulate fractions," and an aliquot
of the suspension was treated with trypsin as described above. Cells
were counted using a hemocytometer, diluting when necessary to main
tain the cell count of the sum of nine squares within 50 to 300.
Protein Determination. Protein content in samples was determined
with a Bio-Rad protein assay kit (Bio-Rad Laboratories, Richmond,
CA), based on the method of Bradford (42), with bovine serum albumin
(Cohn fraction V) as the standard.
RESULTS
EGF Decreases Progesterone Binding in Cultured Breast Car
cinoma Cells. The effect of EGF on progesterone binding to
substratum-adherent breast carcinoma cells was determined
with cells incubated first with EGF for 60 min at 37"C, and
then with [3H]progesterone at 22Â°Cfor 60 min to achieve
maximal binding. EGF decreased cellular specific [3H]proges-
terone binding by 25-40% in T47D, MCF-7, and ZR75-1 cells
oo
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Fig. 1. EGF decreases progesterone binding to cultured human breast carci
noma cells. Adherent breast cancer T47D, MCF-7, or ZR7S-1 cells grown in 2-
cm ' 24 urli culture dishes were washed twice with 2 ml/well of progesterone
binding medium, and then incubated first at 37*C for 60 min in 0.5 ml of binding
medium containing 0.1 to 3.0 nM EGF, and then at 22*C for 60 min with EGF
and 20 nM [3H]progesterone (see "Materials and Methods"). Progesterone binding
is expressed as percentage of that detected in untreated cells Â±SD (n = 6) and
was 1020 Â±40, 481 Â±13, 370 Â±30 (x IO3 sites/cell) for T47D, MCF-7 and
ZR75-1 cells, respectively. A, B, and C, data for T47D, MCF-7, and ZR75-1
cells, respectively.
(Fig. 1, A-C). The effect of EGF was dose dependent with an
EDso value of approximately 0.1 nM. Maximal inhibition of
progesterone binding was achieved at approximately 1 nM EGF.
Since T47D cells metabolize progesterone rapidly, we also
studied the effect of EGF on binding of the nonmetabolizable
progestin R5020. When T47D cells were treated with 3 nM
EGF as described in the legend of Fig. 1 and then with 20 nM[3H]R5020, cellular [3H]R5020 binding was decreased by 30%.
Insulin also decreased progesterone binding to cells by 25-30%.
The EDso for insulin was approximately 1 nM for MCF-7 and
ZR75-1 cells and 10 nM for T47D cells (data not shown).
The influence of order of addition of EGF and progesterone
was tested. An EGF-induced decrease in progesterone binding
of approximately 30% was observed regardless of whether cells
were incubated with EGF prior to or after progesterone addition
(data not shown).
Decreased Progesterone Binding to Receptors Recovered in
Resolved Particulate or Soluble Fractions as a Function of Du
ration of Cellular EGF Treatment. T47D cells contain two
classes of progesterone binding sites that can be demonstrated
in intact cells or cell free preparations (43). The high affinity
sites bind progesterone with a k,\ value of 2 nM and are present
in the soluble fraction of a cell homogenate, whereas the lower
affinity sites bind progesterone with a Acdof 20-60 nM and are
present exclusively in the particulate fraction. To test for pre
ferred inhibition of progesterone binding to receptors in the
soluble or particulate fractions, cells were incubated at 37Â°C
with 20 HM EGF for times extending from 2 to 120 min, and
then processed for preparation of the particulate and soluble
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fractions. The EGF-induced decrease in progesterone binding
to receptors in the soluble fraction was maximal within 2 min
of EGF addition, but greater than 15 min of incubation with
EGF was required to achieve maximal inhibition of progester
one binding to lower affinity receptors in the paniculate fraction
(Fig. 2). Moreover, the magnitude of the EGF-induced decrease
in progesterone binding to the particulate fraction was twice
that observed in the soluble fraction.
EGF Decreases Progesterone Receptor Number without Af
fecting Receptor Affinity. To determine if EGF affects proges
terone receptor number or affinity in T47D cells, we examined
equilibrium progesterone binding to receptors in the soluble
fraction and in the high ionic strength extract of the particulate
fraction following EGF treatment. EGF decreased progesterone
binding in either fraction by one half with no change in affinity
(Fig. 3, Table 1). This effect on receptor number is different
from that shown in Fig. 2, where progesterone binding to
receptors in the soluble fraction of EGF-treated cells grown on
plastic dishes was decreased to a lesser extent than progesterone
binding to receptors in the particulate fraction.
Cells grown in glass roller bottles (Fig. 3), responded con
sistently to EGF with equal decreases in progesterone binding
to receptors in the soluble and particulate fractions, whereas
progesterone receptors in cells grown in plastic wells behaved
consistently in response to EGF as described in Fig. 2. This
could be due to properties induced by cell-substrate interactions
on plastic versus glass. For example, Fourreau-Schneider et al.
(45) showed that MCF-7 cells grown as spheroids on hydro-
phobic plastic coated with 1% Bactoagar have twice as many
progesterone receptors as cells grown as monolayers on hydro-
philic plastic. Gospodarowiz et al. (46) found that the response
of corneal epithelial cells to growth factors depended on cell
substrate: EGF was a mitogen for corneal epithelial cells cul
tured on a collagen gel but not on plastic, with fibroblast growth
factor this response to cell substrate was reversed.
For the studies shown in Figs. 1-3 cells were grown in
untreated serum. Identical studies conducted with cells grown
in DCC-FBS yielded the same findings. In these, however, there
was far more experimental variation resulting from a tendency
of DCC-FBS grown cells to dissociate from the culture dish
(see "Materials and Methods"). All other experiments (Figs.
4-8) cells were grown in DCC-FBS to facilitate comparison of
our results with those of published studies (13, 16, 31, 40, 47)
where DCC-FBS was utilized.
Cellular Progesterone Binding in Response to EGF as a Func-
0.6
0.3
CD
T3
O
OÃ™
1.0 2.0
0.6
0.3
O
O 2.0 4.0
Progesterone Bound (nM)
Fig. 3. Effect of cellular EGF treatment on progesterone receptor number and
affinity. T47D cells, cultured in roller bottles to approximately 80% confluency,
were washed once and then incubated in situ at 37Â°Cfor 60 min in IS ml
progesterone binding medium containing 3 nM EGF or no EGF. The cells were
then washed and homogenized, and the soluble and the high ionic strength extract
of the particulate fraction were prepared and incubated at 4'C for 16 h with 0.4
to 100 nM [3H]progesterone prior to determining binding by the dextran-coated
charcoal assay (see "Materials and Methods"). Replicate samples contained 10
/AI unlabeled progesterone for determination of nonspecific binding. Nonspecific
binding was also determined computationally using the LIGAND program (44)
as well as total receptor number and dissociation constants. Data are shown as
Scatchard plots of progesterone binding to the soluble fraction (A) or high ionic
strength extract of the particulate fraction (B) from EGF-treated cells (O) or
untreated (â€¢)cells.
Table 1 Number and dissociation constant for progesterone receptors from EGF-
treated or untreated T47D cells
Receptor number and dissociation constants Â±SE were determined with the
LIGAND program (44) and are from the data shown in Fig. 3.
Cytosol
EGF (3 nM) fc, (nM)
Receptor number
(pmol/mg
protein)
Particulate extract
Receptor number
(pmol/mg
protein)
I.I Â±0.2
1.4 Â±0.2
6.0 Â±1.0
2.7 Â±0.6
5.3 Â±1.0
4.5 Â±0.5
5.2 Â±0.9
1.9 Â±0.6
IT re
s
100!
50
0 15 30 45 60 120
EGF Incubation Time (min)
Fig. 2. Time course for EGF inhibition of progesterone binding to soluble and
particulate progesterone receptors. T47D cells, grown for 3 days in 55-cm2 Petri
plates to approximately 50% confluency, were washed twice with 10 ml/plate ofprogesterone binding medium and then incubated at 37'C for 2 to 120 min in the
absence or presence of 20 nM EGF in 4.0 ml of progesterone binding medium.Ceils were washed twice with 10 ml of homogenization buffer at 22'C, and the
soluble fraction and the high ionic strength extract of the particulate fraction
were prepared and assayed for progesterone binding at 22"C with 20 nM ['Hi-
progesterone using dextran-coated charcoal to remove unbound ligand (see "Ma
terials and Methods"). Progesterone receptor content is expressed as percentage
of that in samples not treated with EGF â€¢SD (n â€”4) for soluble (O) or particulate
extract (D) fractions. Progesterone binding to soluble and particulate extract
fractions from untreated cells was 5.7 Â±0.2 and 7.9 Â±0.4 fmol progesterone
bound/Mg protein, respectively.
s 140
l
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i
o
*- 70
0.0 1.0 2.0 3.0
Final Cell Density (10 x cells/cm )
Fig. 4. Effect of cell density on EGF receptor number on T47D cells. T47D
cells were seeded at different cell densities (16,000-160,000 cells/well for 3-day
growth or 4,000-40,000 cells/well for 6-day growth) in 2-cm2 24-well culture
dishes to achieve the final cell densities shown after 3 or 6 days in culture. The
culture medium was changed every 2 days. After 3 or 6 days in culture, cells from
three independent wells were counted to determine final cell densities, and
adherent cells in replicate wells were assayed for EGF receptor content (see
"Materials and Methods"). EGF binding is expressed as sites per cell (mean Â±
SD of six independent wells) following growth for 3 (â€¢)or 6 (D) days.
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Fig. 5. Progesterone receptor content in T47D cells incubated for 2 or 8 days
with EGF. T47D cells were plated in 2-cm2 24-well dishes at varying cell densities
(16,000-160,000 cells/well for 2-day growth or 1,000-10,000 cells/well (control)
and 500-5,000 cells/well (EGF treated) for 8-day growth. At 24 h after plating,
1 nM EGF was added to one set of wells at each cell density and all the cells were
grown for either 2 or 8 days with a change in medium and further addition of
EGF every 2 days. After 2 or 8 days of culture the cells from three independent
wells were counted to determine final cell densities, and progesterone binding was
determined by the adherent cell progesterone binding assay (see "Materials and
Methods"). Data show progesterone receptor contents as sites/cell Â±standard
deviation (n â€”6) for 2 (A) or 8 (B) days of culture in absence (O) or presence (â€¢)
of EGF.
8
Time (Days)
Fig. 6. Time course for EGF action as an antagonist or progestin-induced
inhibition of cell growth. T47D cells were plated at 130,000 cells/10 cm2 well
(see "Materials and Methods"). At 24 h after plating, indicated by the arrow,
R5020 (a 1,000-fold concentrated solution in ethanol) or EGF were added to the
cells. Control and EGF-treated cultures received the same amount of ethanol as
R5020 treated cells. Medium containing these agents was changed every 2 days.
Cells were counted on the days as indicated. A, shows a dose-response experiment
for the effect of R5020 on cell reproduction for cells grown 6 days without (â€¢)
or with 1 nM EGF (A); It. shows the time courses of cell growth for untreated
cells (Ãœ),and for cells treated with 100 nM R5020 (â€¢),1 nM EGF (â€¢),or 1 nM
EGF + 100 nM R5020 (O). Values are means Â±SD (n = 3).
tion of Cell Density. EGF receptor density on cultured BSC-1
kidney epithelial cells decreases at high cell density (48). EGF
receptor number in T47D cells also was decreased at high cell
density; there were approximately 5-fold more receptors at
lower than at higher cell density (Fig. 4). This inverse relation
ship between EGF receptor and cell density was also observed
with MCF-7 cells (50,000 and 10,000 sites/cell at 0.5 X IO5
cells/cm2 and at 2.5 x 10s cells/cm2, respectively) and ZR75-1
cells (90,000 and 15,000 sites/cell at 0.5 x 10s cells/cm2 and
at 2.5 x 10s cells/cm2, respectively).
To study the effect of EGF on progesterone binding as a
function of cell density, T47D cells were grown to high or low
cell densities in the absence or presence of 1 HM EGF for 2 or
8 days. In contrast to EGF receptor behavior, progesterone
receptor content of T47D cells was not affected by cell density
(Fig. 5). The decrease in progesterone binding induced in these
cells by EGF was as high as 30-50%, and persisted after 8 days
of EGF treatment (Fig. 5). The magnitude of the decrease in
progesterone binding induced by 2 days of EGF treatment was
not affected by cell density (Fig. 5A). However, of cells treated
for 8 days with EGF, those that had achieved higher densities
O
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Fig. 7. Dose response of EGF or insulin for stimulation of cell growth in the
absence or presence of RS020. For EGF dose-response studies (A), T47D cells
were plated at 30,000 cells/well in 10 cm2 6-well culture dishes as described in
"Materials and Methods." At 24 h after plating, EGF or R5020 was added to the
cells and the culture medium containing these agents was changed every 2 days.
Cells were counted after 6 days of hormone treatment. Insulin dose-response
studies (B) were done as above, except that 50,000 cells/well were plated and
cultured under serum-free conditions (see "Materials and Methods"). Values for
cell numbers are means Â±SD (n = 3) for cells grown in the absence (O) or
presence (â€¢),respectively, of 100 nM R5020.
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Fig. 8. Effect of progestins on EGF receptor number. T47D cells were plated
in 2 cur 24-well dishes at varying cell densities to achieve approximately 50%
confluent cultures after 2, 4, or 6 days of growth (see "Materials and Methods").
All cells were grown for at least two days after seeding prior to progestin addition
and EGF binding assay. For 0 and 12 h time points cells were cultured for 2 days
prior to addition of progestins. For other time periods, progestins were added to
the cells 24 h after plating and the culture medium was changed every 2 days with
fresh additions of progestins. The seeding densities for 0,12 h, and 2-day progestin
treatment times were the same (100,000 cells/well), for 4-day 25,000 cells/well
(control) or 30,000 cells/well (progestin treated), and for 6-day 10,000 cells/well
(control) or 15,000 cells/well (progestin treated). At the times indicated, cell
number was counted and replicate samples were assayed for EGF receptor content(see "Materials and Methods"). Values are means Â±SD (n = 6) for untreated
cells (O), or cells treated with 10 nM progesterone (â€¢),1,000 nM progesterone
(D), or 1 nM R5020(B).
were more responsive to EGF (Fig. 5B) in spite of their lower
EGF receptor levels (Fig. 4).
EGF and Insulin Stimulate Cell Growth and Antagonize Pro-
gestin-induced Inhibition of Cell Growth. Since treating cells
with EGF decreased progesterone binding, experiments were
performed to determine if EGF antagonized progesterone-me
diated inhibition of cell reproduction. Progestins, such as
R5020, inhibit the growth of MCF-7 and T47D cells by 30-
70% (13, 31). R5020 inhibited the growth of T47D cells by
approximately 30% (Fig. 6/4), with an ED5o value of 1 nM. This
is approximately equal to the dissociation constant for R5020
binding to high affinity progesterone receptors (47; and con-
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firmed by us). Inhibition of cell growth induced by R5020
persisted for at least 6 days (Fig. 6B).
EGF stimulated T47D cell growth (Fig. 6B). When cells were
cultured in the presence of both EGF (l HM) and R5020 (100
nM), the effect of EGF on cell growth dominated (Fig. 6B). No
concentration of R5020 tested (up to 1,000 HM) overcame the
growth stimulatory effect of 1 nM EGF (Fig. 6/4). EGF stimu
lated cell reproduction with an EDSOvalue of <0.1 nM and a
maximal response at 1 nM (Fig. 7A). T47D cells seeded at
lower density (30,000 cells/10 cm2 area) consistently had a
greater response to EGF (2- to 3-fold) than those seeded at a
higher density (130,000 cells/10 cm2 area; 1.5- to 2-fold stim
ulation, compare Figs. 1A and 6B). Approximately 0.1 nM EGF
completely overcame the growth inhibitory effect of 100 nM
R5020 (Fig. 7A). The growth studies described above for EGF-
treated cells were conducted in RPMI 1640 medium containing
5% DCC-FBS (see "Materials and Methods"). Identical re
sponses to progestins and EGF were obtained in medium con
taining untreated serum and in serum free medium (data not
shown).
Insulin did not stimulate T47D cell reproduction in medium
containing serum (not shown), but in serum-free medium it
increased cell number by approximately twofold (Fig. IB). The
EDso value for this response was approximately 0.1 MMinsulin,
and the response was maximal at 1 MMinsulin (Fig. IB). Insulin
also completely overcame inhibition of cell growth by 100 nM
R5020, but a very high insulin concentration (1 MMor greater)
was required (Fig. IB).
Progestins Increase EGF Receptor Number. Progestins can
increase both EGF and insulin receptor numbers in T47D cells
(13, 14). The increase in insulin receptors was observed after 1
day of progestin treatment, but after 4 days of progestin treat
ment, insulin receptor number returned to approximately the
level in untreated cells (13). An increase in EGF receptor
number was evident after l h treatment with R5020 and per
sisted for 24 h, the maximal time studied (13). We performed
experiments to determine if EGF receptors were maintained in
an up-regulated state upon longer progestin treatment (>1 day).
Progesterone or R5020 increased EGF receptor number 1.5- to
2-fold during a 12-h incubation (Fig. 8). However, when cells
were incubated with progestins for 6 days, EGF receptor num
ber returned to levels characteristic of untreated cells. At a
lower progesterone dose (10 nM), EGF receptors returned to a
level characteristic of untreated cells after 2 days of treatment,
possibly due to progesterone metabolism (49).
DISCUSSION
EGF regulates progesterone binding activity in cultured
breast cancer cells and attenuates progestin-induced inhibition
of their reproduction. The ED5o value for both these responses
was 0.1 nM EGF (Figs. 1 and 7), which is approximately the kÂ¿
value for a very high affinity class of cellular EGF binding
detected in T47D cells (14) and other cell lines (50-52). This
suggests the involvement of very high affinity EGF binding
sites in decreasing progesterone binding. EGF also decreased
dexamethasone binding to glucocorticoid receptors in HBL 100
cells (nontumorigenic human breast epithelial cells) in a dose-
dependent manner with an EDso value of 0.1 nM (53).
The mechanisms by which EGF decreases progesterone or
glucocorticoid binding have not been established. For both
progesterone (Fig. 3) and glucocorticoid (53) binding, EGF
decreased total steroid binding activity without affecting affin
ity. These results are similar to findings of Butler et al. (16),
who showed that insulin decreased total estradici receptor
number in MCF-7 cells without affecting affinity, and that of
Roos et al. (54), who reported that TPA treatment decreased
progesterone receptor number in T47D cells with no change in
receptor affinity. EGF decreased progesterone (Fig. 2) or glu
cocorticoid (53) binding rapidly. We have demonstrated a rapid
EGF-induced phosphorylation of glucocorticoid receptors on
tyrosine and serine residues in HBL 100 cells, suggesting a
possible direct action of EGF receptor kinase on glucocorticoid
receptors (55). However, neither EGF nor TPA induced pro
gesterone receptor phosphorylation in intact T47D cells (56).
This shows that the EGF-induced decrease in progesterone
receptor binding is not caused by a change in the phosphoryla
tion state of progesterone receptors. EGF, insulin, and TPA
must therefore decrease progesterone binding in intact cells by
acting through other intracellular mediators.
Either EGF or insulin stimulated T47D cell growth in the
absence of serum (Fig. 7). Although EGF stimulated T47D cell
growth in the presence of serum, insulin did not, suggesting
that insulin-like growth factors in serum can mask the response
to insulin. Our data showing that micromolar insulin concen
trations were required to stimulate T47D cell growth are in
agreement with published findings of Furlanetto and DiCarlo
(57). Their studies on competition between insulin and soma-
tomedin-C (IGF-I) for binding to cultured breast cancer cells
indicate that insulin stimulates cell growth by binding to IGF-
I receptors. A high concentration (approximately 1 MM) of
insulin also was required to stimulate cell reproduction and
overcome progestin-induced inhibition of cell reproduction
(Fig. IB), indicating that these responses to insulin are me
diated through IGF-I receptors. The findings that nanomolar
insulin was half-maximal for decreasing progesterone binding,
but that micromolar insulin was required for stimulating cell
growth and antagonizing progestin-induced inhibition of cell
growth show that the former is not causal for the latter. The
finding that insulin overcame progestin-induced cell growth
inhibition only in serum-free culture, but that EGF had this
effect either in the presence of serum or in serum-free culture,
suggest that EGF and insulin antagonize progestin action via
different mechanisms.
In agreement with findings of Murphy et al. (14), who studied
only the short-term aspects of the phenomenon, progestins
increased EGF receptor number in T47D cells (Fig. 8). We
discovered that after 6 days of progestin treatment, EGF recep
tors in T47D cells returned to levels characteristic of untreated
cells (Fig. 8). This was also observed with cells subjected to
frequent changes of medium containing the progestin R5020,
which is relatively stable to metabolism. Therefore, the loss of
progestin-induced upregulation of EGF receptors is unlikely to
be caused by progestin metabolism. Progestins did not increase
EGF receptor number in the experiment described in Fig. 8 by
altering cell density, since that factor was controlled experi
mentally. Recently, Murphy et al. (58) showed that progestins
increased EGF receptor mRNA (2- to 3-fold) in T47D cells and
this increase was proportional to the progestin-induced increase
in EGF binding. The mechanism by which progestins increase
insulin receptor numbers is not known (13). Cell growth inhib
itors such as the antiestrogen tamoxifen induce release of
transforming growth factors such as TGF-/8 by cells (22). TGF-
ÃŸhas been reported to increase EGF receptor number in normal
rat kidney fibroblasts (59) and rat ovarian granulosa cells (60).
Recently, Fernandez-Pol et al. (61) demonstrated that EGF
induces the synthesis of its own mRNA, and that TGF-/3
potentiates this response to EGF in cultured MDA-468 human
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breast carcinoma cells. Since progestins increase the number of
EGF (14) and insulin (13) receptors, it has been suggested that
these steroids may sensitize cells to growth factor action (14).
Our studies indicate that this was not the case for T47D cells
(Fig. 7).
Both EGF (25-28, 30) and progesterone (28, 32), in concert
with other hormones such as estrogen, glucocorticoid, thyroid
hormone, insulin, and prolactin, are involved in the growth,
development of and lactation by mammary glands (32). Recent
studies suggest that EGF is essential for lactation and for
production of milk proteins (29, 62), whereas progesterone
inhibits lactation during pregnancy (32). When lactation ensues
following parturition, plasma progesterone level falls (32) and
lactating mammary glands have no detectable progesterone
receptors (63), but possess EGF receptors. Our findings suggest
that EGF could contribute to synthesis of milk proteins during
lactation by down-regulating progesterone receptors.
The progestin R5020 inhibited the growth of cultured T47D
cells by approximately 40% (Fig. 6). Our results are in agree
ment with findings that progestins inhibited the growth of
cultured human breast carcinoma MCF-7 cells (31), T47D cells
(13) and cultured human endometrial carcinoma cells (64) to
similar extents. EGF, even at very low concentration, overcame
the cell growth inhibitory effects of R5020 (Figs. 6 and 7) or
dexamethasone (53) and partially overcame the growth inhibi
tory effect of antiestrogens (65) on steroid hormone-responsive
cultured human breast epithelial cells. There are reports of
other growth factors attenuating growth inhibitory responses
to steroid hormones. High concentrations of insulin, apparently
acting as IGF-I, overcame the growth inhibitory responses of
cultured MCF-7 cells to the antiestrogen tamoxifen (16), and
platelet-derived growth factor overcame glucocorticoid-induced
cell cycle arrest in a cultured ductus deferens smooth muscle
tumor cell line (66).
Progestins are exploited in hormone therapy of advanced
breast cancer (67, 68), and progesterone receptor status is an
important predictor of the response to endocrine therapy (69-
72). Studies with biopsied breast tumors reveal a high EGF
receptor number associated with low estrogen or progesterone
receptor content (17, 18). Our studies indicate that down-
regulation of steroid receptors by EGF could contribute to this
condition.
We have demonstrated that EGF or insulin, the latter acting
as IGF-I, stimulate proliferation of cultured breast carcinoma
T47D cells and overcome progestin-induced inhibition of cell
growth. The present study taken together with studies by others
(16, 53, 66, 65) suggests that growth factors can competitively
abolish inhibition of cell growth in response to steroids. Our
findings that EGF or a high level of insulin overcame progestin-
induced inhibition of cell growth in cultured human breast
carcinoma cells show that secreted TGF-a-like factors or se
creted IGF-I-like peptides may antagonize steroid action and
lead to failures in progestin therapy for breast cancer.
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